Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
(Reuters) – Gilead Sciences (NASDAQ: ) said on Saturday it has entered into a partnership with Denmark’s LEO Pharma to develop programs to treat patients with infectious diseases.
The Danish company will be eligible to receive up to $1.7 billion in payments, including a $250 million upfront payment from Gilead.
In return, Gilead will have worldwide rights to develop, manufacture and commercialize the small molecule oral STAT6 (signal transducer and activator of transcription 6) program.
Targeting STAT6 has shown potential to treat many diseases such as atopic dermatitis, asthma and COPD.
LEO Pharma may receive tiered royalties on sales of STAT6 products ranging from the high single digits to the mid-teens.
The transaction is expected to reduce Gilead’s GAAP and non-GAAP 2025 earnings per share by approximately $0.15 – $0.17.
“Together with Leo Pharma, we hope to explore the potential of the STAT6 pathway to bring an oral alternative to patients suffering from chronic inflammatory disease,” said Flavius Martin, executive vice president of research at Gilead Sciences.
